Patents by Inventor Sudhir R. Sahasrabudhe

Sudhir R. Sahasrabudhe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of Treating Multiple Myeloma and Resistant Cancers
    Publication number: 20160271133
    Abstract: Erastin analogs are useful in treating various cancers, particularly multiple myeloma. Erastin analogs are also useful in treating cancers that are resistant to other anticancer agents. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: May 17, 2016
    Publication date: September 22, 2016
    Inventors: Paul B. Robbins, Sudhir R. Sahasrabudhe
  • Methods of Treating Multiple Myeloma and Resistant Cancers
    Publication number: 20160015710
    Abstract: Erastin analogs are useful in treating various cancers, particularly multiple myeloma. Erastin analogs are also useful in treating cancers that are resistant to other anticancer agents. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: August 20, 2015
    Publication date: January 21, 2016
    Inventors: Paul B. Robbins, Sudhir R. Sahasrabudhe
  • METHODS OF TREATING MULTIPLE MYELOMA AND RESISTANT CANCERS
    Publication number: 20140227221
    Abstract: Erastin analogs are useful in treating various cancers, particularly multiple myeloma. Erastin analogs are also useful in treating cancers that are resistant to other anticancer agents.
    Type: Application
    Filed: December 4, 2013
    Publication date: August 14, 2014
    Applicant: Prolexys Pharmaceuticals, Inc.
    Inventors: Paul B. Robbins, Sudhir R. Sahasrabudhe
  • 3-aryl-substituted quinazolones, and uses thereof
    Patent number: 8575143
    Abstract: Compounds represented by Structural Formula (I): are useful, for example, in the effective killing or reducing the rate of proliferation of cancer cells, such as in patients suffering from cancer. In addition to the compounds themselves, the invention provides pharmaceutical compositions of the compounds and method of treatment using the compounds.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: November 5, 2013
    Assignee: Prolexys Pharmaceuticals, Inc.
    Inventors: Longwu Qi, Raj Gopal Venkat, Michael Pierce, Paul B. Robbins, Sudhir R. Sahasrabudhe, Robert Selliah
  • Quinoxaline derivatives as antitumor agents
    Patent number: 8518959
    Abstract: The invention relates to methods of screening for binding partners, especially binding partners essential for the biological activity of erastin (e.g. VDACs such as VDAC3). The invention also provides reagents and methods for effective killing of cancer cells with erastin and related compounds or derivatives.
    Type: Grant
    Filed: January 25, 2006
    Date of Patent: August 27, 2013
    Assignee: Prolexys Pharmaceuticals, Inc.
    Inventors: Robert R. Becklin, Cindy Lou Chepanoske, John M. Peltier, Longwu Qi, Paul B. Robbins, Sudhir R. Sahasrabudhe, Robert Selliah, Keith Simmon, Brent R. Stockwell, Raj Gopal Venkat, Moritz von Rechenberg, Eugene Y. Zhen
  • METHODS OF TREATING MULTIPLE MYELOMA AND RESISTANT CANCERS
    Publication number: 20110123486
    Abstract: Erastin analogs are useful in treating various cancers, particularly multiple myeloma. Erastin analogs are also useful in treating cancers that are resistant to other anticancer agents.
    Type: Application
    Filed: June 25, 2008
    Publication date: May 26, 2011
    Applicant: Prolexys Pharmaceuticals, Inc.
    Inventors: Paul B Robbins, Sudhir R. Sahasrabudhe
  • 3-Aryl-Substituted Quinazolones, and Uses Thereof
    Publication number: 20110092489
    Abstract: Compounds represented by Structural Formula (I): are useful, for example, in the effective killing or reducing the rate of proliferation of cancer cells, such as in patients suffering from cancer. In addition to the compounds themselves, the invention provides pharmaceutical compositions of the compounds and method of treatment using the compounds.
    Type: Application
    Filed: December 22, 2006
    Publication date: April 21, 2011
    Applicant: Prolexys Pharmaceuticals ,Inc.
    Inventors: Longwu QI, Raj Gopal Venkat, Michael Pierce, Paul B. Robbins, Sudhir R. Sahasrabudhe, Robert Selliah
  • Erastin and erastin binding proteins, and uses thereof
    Patent number: 7615554
    Abstract: The invention relates to methods of screening for binding partners, especially binding partners essential for the biological activity of erastin (e.g. VDACs such as VDAC3). The invention also provides reagents and methods for effective killing of cancer cells with erastin and related compounds or derivatives.
    Type: Grant
    Filed: January 25, 2006
    Date of Patent: November 10, 2009
    Assignees: Prolexys Pharmaceuticals, Inc., Whitehead Institute for Biomedical Research, The Trustees of Columbia University in the City of New York
    Inventors: Robert Selliah, Longwu Qi, Paul B. Robbins, Sudhir R. Sahasrabudhe, Brent R. Stockwell, Raj Gopal Venkat
  • Quinoxaline Derivatives as Antitumor Agents
    Publication number: 20090214465
    Abstract: The invention relates to methods of screening for binding partners, especially binding partners essential for the biological activity of erastin (e.g. VDACs such as VDAC3). The invention also provides reagents and methods for effective killing of cancer cells with erastin and related compounds or derivatives.
    Type: Application
    Filed: January 25, 2006
    Publication date: August 27, 2009
    Applicants: PROLEXYS PHARMACEUTICALS, INC., WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF
    Inventors: Robert R. Becklin, Cindy Lou Chepanoske, John M. Peltier, Longwu Qi, Paul B. Robbins, Sudhir R. Sahasrabudhe, Robert Selliah, Keith Simmon, Brent R. Stockwell, Raj Gopal Venkat, Moritz von Rechenberg, Eugene Y. Zhen
  • Fused Pyrimidones and Thiopyrimidones, and Uses Thereof
    Publication number: 20090170834
    Abstract: Compounds represented by Structural Formula (I): are useful, for example, in the effective killing or reduction in rate of proliferation of cancer cells, such as in patients suffering from cancer. In addition to the compounds themselves, the invention provides pharmaceutical compositions of the compounds and method of treatment using the compounds.
    Type: Application
    Filed: December 22, 2006
    Publication date: July 2, 2009
    Applicant: PROLEXYS PHARMACEUTICALS, INC.
    Inventors: Raj Gopal Venkat, Longwu Qi, Michael Pierce, Paul B. Robbins, Sudhir R. Sahasrabudhe, Robert Selliah
  • Non-peptidyl agents with pHSP20-like activity, and uses thereof
    Publication number: 20090136561
    Abstract: The present invention provides compositions and methods for modulating smooth muscle cells. The present invention also provides methods of identifying small molecule candidate therapeutic agents for modulating smooth muscle.
    Type: Application
    Filed: October 20, 2008
    Publication date: May 28, 2009
    Applicant: Prolexys Pharmaceuticals, Inc.
    Inventors: Moritz von Rechenberg, John M. Peltier, Sudhir R. Sahasrabudhe, Srdjan Askovic, Robert Selliah, Thomas Zarembinski
  • Method of determining the degree of aggregation of the .beta.-A4 peptide
    Patent number: 5919631
    Abstract: A method of determining the degree of aggregation of the .beta.A4 peptide is disclosed. The method comprises reacting the protein with a suitable binding agent which is capable of binding the .beta.A4 peptide only in its non-aggregated state to form an amount of protein bound binding reagent. The amount of protein bound binding agent is then measured.
    Type: Grant
    Filed: July 17, 1996
    Date of Patent: July 6, 1999
    Assignee: Hoechst Marion Roussel, Inc.
    Inventors: Shefali Goyal, Joseph W. Paul, Norbert G. Riedel, Sudhir R. Sahasrabudhe